Extending the clinical benefit of proven cancer therapies

Vicus is employing immunotherapy to selectively target signaling pathways that lead to tumor-promoting inflammation and tumor evasion of the immune system. Our goal is to safely and significantly extend the clinical benefit of proven cancer therapies.

About Vicus

We are an immuno-oncology company developing breakthrough immunotherapies for patients with solid-tumor cancers. We are focused on the development and commercialization of our lead product candidate, VT-122, a immunotherapy for advanced liver cancer patients receiving sorafenib and for metastatic pancreatic cancer patients receiving nab-paclitaxel  and gemcitabine.